User login
Key clinical point: In the real-world setting, patients with unresectable HCC who did not meet clinical trial criteria had similar responses to the treatment combination as those who met clinical trial criteria.
Major finding: The objective response rates and disease control rates of 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively, were similar between patients who met and did not meet the IMbrave150 clinical trial criteria, as were safety profiles.
Study details: The data come from a multicenter study of 64 adults with unresectable hepatocellular carcinoma, including 46 who did not meet the study criteria. All patients were treated with a combination of atezolizumab plus bevacizumab. Treatment response and safety issues were assessed at 6 weeks and 12 weeks.
Disclosures: The study was supported by the Japan Agency for Medical Research and Development. The researchers had no financial conflicts to disclose.
Source: Sho T et al. Hepatol Res. 2021 Jul 10. doi: 10.1111/hepr.13693.
Key clinical point: In the real-world setting, patients with unresectable HCC who did not meet clinical trial criteria had similar responses to the treatment combination as those who met clinical trial criteria.
Major finding: The objective response rates and disease control rates of 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively, were similar between patients who met and did not meet the IMbrave150 clinical trial criteria, as were safety profiles.
Study details: The data come from a multicenter study of 64 adults with unresectable hepatocellular carcinoma, including 46 who did not meet the study criteria. All patients were treated with a combination of atezolizumab plus bevacizumab. Treatment response and safety issues were assessed at 6 weeks and 12 weeks.
Disclosures: The study was supported by the Japan Agency for Medical Research and Development. The researchers had no financial conflicts to disclose.
Source: Sho T et al. Hepatol Res. 2021 Jul 10. doi: 10.1111/hepr.13693.
Key clinical point: In the real-world setting, patients with unresectable HCC who did not meet clinical trial criteria had similar responses to the treatment combination as those who met clinical trial criteria.
Major finding: The objective response rates and disease control rates of 5.2% and 82.8% at 6 weeks and 10.0% and 84.0% at 12 weeks, respectively, were similar between patients who met and did not meet the IMbrave150 clinical trial criteria, as were safety profiles.
Study details: The data come from a multicenter study of 64 adults with unresectable hepatocellular carcinoma, including 46 who did not meet the study criteria. All patients were treated with a combination of atezolizumab plus bevacizumab. Treatment response and safety issues were assessed at 6 weeks and 12 weeks.
Disclosures: The study was supported by the Japan Agency for Medical Research and Development. The researchers had no financial conflicts to disclose.
Source: Sho T et al. Hepatol Res. 2021 Jul 10. doi: 10.1111/hepr.13693.